Liberum Capital assumed coverage on shares of ISIS Pharmaceuticals (NASDAQ: ISIS) in a report released on Friday. The firm issued a hold rating and a $69.00 target price on the stock.
Several other analysts have also recently commented on the stock. Analysts at Piper Jaffray raised their price target on shares of ISIS Pharmaceuticals to $11.00 in a research note to investors on Wednesday, January 30th. Separately, analysts at Needham & Company raised their price target on shares of ISIS Pharmaceuticals from $14.00 to $18.00 in a research note to investors on Wednesday, January 30th. They now have a buy rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of ISIS Pharmaceuticals from $13.00 to $19.00 in a research note to investors on Wednesday, January 30th. They now have a buy rating on the stock.
Four investment analysts have rated the stock with a buy rating, four have given a hold rating, and one has given a sell rating to the company’s stock. ISIS Pharmaceuticals currently has an average rating of overweight and an average target price of $13.14.
Shares of ISIS Pharmaceuticals traded up 3.60% during mid-day trading on Friday, hitting $14.95. ISIS Pharmaceuticals has a 52 week low of $7.02 and a 52 week high of $15.61. The stock’s 50-day moving average is currently $13.33. The company’s market cap is $1.513 billion.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
